BioPorto A/S (THOXF)
| Market Cap | 88.66M -4.0% |
| Revenue (ttm) | 6.33M +11.2% |
| Net Income | -12.91M |
| EPS | -0.02 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 31,000 |
| Open | 0.1490 |
| Previous Close | n/a |
| Day's Range | 0.1490 - 0.1490 |
| 52-Week Range | 0.1490 - 0.1490 |
| Beta | 1.38 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 20, 2026 |
About BioPorto
BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnos... [Read more]
Financial Performance
In 2025, BioPorto's revenue was 40.29 million, an increase of 11.16% compared to the previous year's 36.24 million. Losses were -82.12 million, 20.3% more than in 2024.
Financial numbers in DKK Financial StatementsNews
Grant of Warrants
Copenhagen, Denmark, June 15, 2026, (GLOBE NEWSWIRE) – The Board of Directors of BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) has today decided to issue a total of 1,200,000 warrants to mem...
BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback
June 9, 2026 Announcement no. 12 BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback COPENHAGEN, DENMARK, June 9, 2026 – BioPorto A/S (“BioPorto” ...
BioPorto Earnings release: Q1 2026
BioPorto released its Q1 2026 earnings on May 21, 2026, summarizing the period's financial results.
BioPorto Slides: Q1 2026
BioPorto has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 21, 2026.
BioPorto announces Interim Result for the First Quarter of 2026
May 21, 2026 Announcement no. 11 BioPorto announces Interim Result for the First Quarter of 2026 Copenhagen, De...
BioPorto A/S to host an investor webcast on the results for the first quarter of 2026
May 12, 2026 News release BioPorto A/S to h ost an investor webcast on the results for the first quarter of 202 6 COPENHAGEN, DENMARK, May 12, 2026 (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto o...
BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis
March 31, 2026 Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 – BioPor...
BioPorto Annual report: Q4 2025
BioPorto has published its Q4 2025 annual report on March 26, 2026.
BioPorto Slides: Q4 2025
BioPorto has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 26, 2026.
Notice convening the Annual General Meeting in BioPorto A/S
26 March 2026 Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Compa...
BioPorto announces the Annual Report for 2025
March 26, 2026 Announcement no. 04 ...
BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026
March 18, 2026 Announcement no. 03 BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026 COPENHAGEN, DENMARK, March 18, 2026 –...
BioPorto Press release: Guidance
BioPorto issued a press release on February 6, 2026, disclosing material business information to investors.
BioPorto Slides: Guidance
BioPorto has posted slides in relation to its latest quarterly earnings report, which was published on February 6, 2026.
BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update
February 5, 2026 Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update ...
BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes
24 November 2025 Announcement no. 27 BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number o...
BioPorto Quarterly report: Q3 2025
BioPorto has published its Q3 2025 quarterly earnings report on November 19, 2025.
BioPorto Slides: Q3 2025
BioPorto has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 19, 2025.
Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S
13 November 2025 Announcement no. 25 Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximat...
BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement
13 November 2025 Announcement no. 24 THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR SOU...
BioPorto Press release: Strategy update
BioPorto issued a press release on November 6, 2025, disclosing material business information to investors.
BioPorto Slides: Strategy update
BioPorto has posted slides in relation to its latest quarterly earnings report, which was published on November 6, 2025.
Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025
Copenhagen, Denmark, November 4, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR), today pre-announced the key financial results for the third quarter of 2025 and revis...
BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented
September 26, 2025 News Release BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented COPENHAGEN, DENMARK and BOSTON, MA, USA, September 26 – BioPorto A/S (“...
BioPorto Transcript: Status update
Kidney care is facing a global epidemic of AKI and CKD, with advances in biomarkers, AI, and pediatric devices improving early detection and outcomes. However, workforce shortages, resource constraints, and access disparities challenge care delivery, making interdisciplinary coordination and patient advocacy essential.